AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (475.9 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Clinical Research | Publishing Language: Chinese

Application value of radiotherapy combined with immunotherapy in elderly patients with advanced non-small cell lung cancer

Xiaoli Yuan1,2, Yang Li2, Congming Liu2, Qiju Li2, Feng Wang1( )
Department of Oncology, West China Hospital, Sichuan University, Chengdu 610000, China
Department of Oncology, First People′s Hospital of Liangshan Yi Autonomous Prefecture, Xichang 615000, Sichuan Province, China
Show Author Information

Abstract

Objective

To analyze the application value of radiotherapy combined with immunotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC).

Methods

A total of 206 elderly patients with advanced NSCLC admitted to the First People′s Hospital of Liangshan Yi Autonomous Prefecture from January 2018 to August 2023 were selected as the study subjects. According to the treatment regimens, the patients were divided into an immunotherapy group (n = 101) treated with programmed cell death receptor 1 (PD-1) immune checkpoint inhibitors and a combination therapy group (n = 105) treated with PD-1 inhibitors combined with volume rotation intensity modulated radiation therapy (VMAT). The two groups were compare in the clinical efficacy, T-cell subsets (CD4+, CD8+, CD4+/CD8+), pulmonary function [forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC] before and after treatment, and adverse reactions. SPSS 25.0 was used for data processing. Kaplan-Meier survival curves were used to analyze the difference in progression-free survival (PFS) at 15 months after the beginning of treatment in the two groups.

Results

The objective response rate (50.48% vs 35.64%) and disease control rate (81.90% vs 69.31%) in the combination therapy group were higher than those in the immunotherapy group (P<0.05). After the treatment, CD4+, CD4+/CD8+, FEV1, FVC and FEV1/FVC in both groups increased as compared with before treatment (P<0.05), and the above indicators in the combination therapy group after treatment were higher than those in the immunotherapy group (P<0.05). With 15 months of treatment as the end point, the disease progression rate was 30.48% (32/105) in the combination therapy group and 48.51% (49/101) in the immunotherapy group. Kaplan-Meier curve analysis showed that the median PFS of the combination therapy group [12.41 months (95%CI 11.564-13.255)] was significantly longer than that of the immunotherapy group [10.56 months (95%CI 9.576-11.553)], and the difference was statistically significant (Log-rank χ2=7.465, P=0.006).

Conclusion

VMAT combined with PD-1 inhibitor immunotherapy not only helps enhance the clinical efficacy in elderly patients with advanced NSCLC with good safety but also has positive significance in improving immunity function and pulmonary function and increasing PFS.

CLC number: R734.2; R592 Document code: A

References

【1】
【1】
 
 
Chinese Journal of Multiple Organ Diseases in the Elderly
Pages 97-101

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Yuan X, Li Y, Liu C, et al. Application value of radiotherapy combined with immunotherapy in elderly patients with advanced non-small cell lung cancer. Chinese Journal of Multiple Organ Diseases in the Elderly, 2026, 25(2): 97-101. https://doi.org/10.11915/j.issn.1671-5403.2026.02.022

1

Views

0

Downloads

0

Crossref

Received: 18 January 2025
Accepted: 29 April 2025
Published: 28 February 2026
© 2026 Chinese Journal of Multiple Organ Diseases in the Elderly